Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
Overview of INmune Bio Inc
INmune Bio Inc (NASDAQ: INMB) is a clinical-stage biotechnology company specializing in the development of novel immunotherapies. With a unique commitment to harnessing the patient’s innate immune system, the company’s approach is grounded in precision medicine and innovative biological mechanisms. By targeting key drivers of immune dysfunction, INmune Bio aims to address complex and life-threatening conditions in oncology, neurodegenerative diseases, and chronic inflammation.
Core Business and Value Proposition
At its core, INmune Bio concentrates on reprogramming the body’s natural defense mechanisms to combat disease. The company operates two major product platforms, each designed to tackle distinct pathological processes:
- The Dominant-Negative TNF (DN-TNF) Platform: This platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor (sTNF) without interfering with trans-membrane TNF or TNF receptors. This selective inhibition aims to alleviate chronic inflammation and restore normal immune function. Product candidates within this platform are being assessed in clinical trials for conditions such as cancer, early Alzheimer’s disease, and treatment-resistant psychiatric disorders.
- The Natural Killer (NK) Cell Priming Platform: INKmune, the flagship product of this platform, employs a pharmaceutical-grade, replication-incompetent human tumor cell line to prime resting NK cells into tumor killing memory-like NK cells. This therapy is designed to eliminate residual malignant cells by enhancing the cytotoxic function of NK cells, particularly in a hostile tumor microenvironment where conventional therapies may fall short.
Scientific Foundations and Mechanism of Action
INmune Bio’s approach is deeply rooted in immunology and cellular biology. By targeting the innate immune system, the company seeks to modulate critical pathways that drive chronic disease. The DN-TNF platform focuses on the inflammatory cascade by reducing soluble TNF levels, which may contribute to neuroinflammation and cancer progression. In parallel, the INKmune platform provides multi-channel activation signals to NK cells, thereby converting them into potent, long-lived effectors capable of recognizing and eliminating a broad spectrum of tumors.
Clinical Development and Pipeline
The company’s pipeline is robust and comprehensive, with multiple product candidates under clinical evaluation. The development strategy emphasizes the use of precision medicine techniques tailored to patient-specific biomarkers. Candidates such as INKmune, XPro™, and INB03 are undergoing various stages of clinical trials in diseases ranging from metastatic cancers to early Alzheimer’s disease. Each clinical program is designed to validate the therapeutic potential through a mechanism of action that addresses the underlying pathology at a cellular level.
Market Position and Competitive Landscape
Despite operating in a field characterized by intense competition and rapid scientific advances, INmune Bio differentiates itself with its dual-platform approach and commitment to leveraging both innate immune modulation and precision medicine. While many biotechnology companies focus on a single therapeutic area or mechanism, INmune Bio’s diversified pipeline offers a multi-pronged strategy to tackle residual and treatment-resistant disease. This positioning is integral to its strategy to fill gaps in current treatment paradigms.
Precision Medicine and Patient-Centric Approach
INmune Bio’s research and development are anchored in the principles of precision medicine. By identifying patients with specific biomarkers indicative of immune dysfunction, the company aims to tailor its therapies for maximal efficacy. This patient-centric focus is supported by rigorous clinical trial designs that yield detailed insights into immunologic responses, enhancing the overall therapeutic index of its investigational products.
Clinical Trial Design and Regulatory Environment
The company’s clinical trials are structured to meet high standards of scientific rigor and regulatory compliance. With trial methodologies that integrate novel endpoints and advanced biomarker assessments, every study is designed to generate reproducible and meaningful data. Although all clinical data are subject to the uncertainties inherent in early-stage research, INmune Bio’s protocols underscore its commitment to safety and efficacy without resorting to time-sensitive claims.
Scientific Collaboration and Expertise
INmune Bio benefits from close collaborations with academic institutions, leading clinical researchers, and renowned experts in neuropsychology and immunology. These partnerships reinforce the company’s technical expertise and provide a foundation for its complex therapeutic strategies. The cross-disciplinary collaboration helps ensure that each investigational product is backed by robust preclinical data and a thorough understanding of the underlying disease mechanisms.
Conclusion
In summary, INmune Bio Inc represents a sophisticated and methodical approach to addressing unmet medical needs through innovative immunotherapy solutions. By leveraging two distinct but complementary product platforms, the company works at the intersection of oncology, immunology, and neuroscience. Its rigorous clinical trial programs, focus on precision medicine, and deep-rooted scientific expertise have positioned it as an important player in the evolving landscape of clinical-stage biotechnology. The comprehensive strategy adopted by INmune Bio is a testament to its mission to harness the innate immune system to fight disease in a targeted, efficient, and ultimately patient-friendly manner.
INmune Bio (NASDAQ: INMB) announces publication in Cell Reports demonstrating XPro™'s ability to promote remyelination in demyelinating disease animal models. The study, led by Dr. Leslie Probert at Hellenic Pasteur Institute, shows that XPro1595 converts microglia from damaging to reparative cells by blocking soluble TNF. This research has implications for treating various CNS diseases, including Alzheimer's Disease, where myelin loss compromises neuron function. The company expects to report top-line cognitive results from its Phase II Early AD patients trial in first half of 2025.
INmune Bio (NASDAQ: INMB) has announced it will host a conference call on October 31, 2024, at 4:30 PM EDT to discuss its third quarter 2024 financial results and provide a corporate update. The clinical-stage inflammation and immunology company, which focuses on microglial activation and neuroinflammation in Alzheimer's Disease, will make the call available via phone and webcast. A transcript will be provided approximately 24 hours after the call, and a replay will be accessible through November 7, 2024.
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company focusing on Alzheimer's Disease (AD), has announced its participation in the upcoming Maxim Healthcare Virtual Summit. The event is scheduled for October 15-17, 2024.
INmune Bio's management will be presenting at the summit on October 15, 2024, at 12:20 PM Eastern Time. The presentation will take the format of a fireside chat, and the company will also be available for one-on-one virtual meetings with attendees. Interested parties can register for the webcast through the provided link.
This participation provides an opportunity for INmune Bio to showcase its work on targeting microglial activation and neuroinflammation as potential causes of Alzheimer's Disease to healthcare industry professionals and investors.
INmune Bio Inc. (NASDAQ: INMB) has completed enrollment for its Phase 2 trial in Early Alzheimer's Disease (AD). The global, blinded, randomized trial, known as AD02, focuses on patients with Early AD and biomarkers of elevated neuroinflammation. The company closed enrollment on September 27, 2024, after determining that ongoing screenings would meet the target of 201 patients. Patients currently in the screening process remain eligible, potentially leading to modest over-enrollment.
CJ Barnum PhD, VP of CNS Drug Development and AD02 trial leader, emphasized the significance of this milestone for INmune Bio, its partners, and trial participants. He noted that exceeding the 201-patient goal will enhance the trial's statistical power, expressing anticipation for the final study results.
INmune Bio Inc. (NASDAQ: INMB) has announced initial results from the first patient cohort in its Phase I/II trial of INKmune™, a Natural Killer (NK) cell therapy for metastatic Castration-Resistant Prostate Cancer (mCRPC). The trial, named CaRe PC, has shown excellent safety profile with all patients receiving treatment as out-patients without pre-medication. Even at the lowest dose, there is clear evidence of persistent immunologic effects.
Key findings include:
- Changes in phenotype and function of patients' NK cells
- Increase in circulating activated NK cells in 2 of 3 patients
- Increased NK cell function sustained for over 40 days after final infusion in all patients
- One patient showed a transient 21% decrease in PSA associated with increased NK cell activity
The second dosing cohort has completed, and the third cohort is expected to begin in about 30 days, with doses 3 and 5 times higher than the first cohort, respectively.
INmune Bio Inc. (NASDAQ: INMB) announced results from an additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease trial. The analysis showed exceptional performance of the novel cognitive measure EMACC and a highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Key findings include:
1. A highly significant correlation (p<0.001) between baseline scores on EMACC and CDR-SB.
2. High reliability of EMACC with a correlation of 0.93 between screening and first study visit.
3. EMACC's ability to differentiate between disease stages with an effect size of 0.87 (p<.0001).
The company believes these results validate their trial design and endpoint selection, potentially de-risking their clinical program compared to traditional AD drug development approaches.
INmune Bio Inc. (Nasdaq: INMB) has announced a $13.0 million registered direct offering of common stock and warrants. The company will sell 2,341,260 shares of common stock and warrants to purchase an additional 2,341,260 shares. The combined purchase price is $5.50 per share and warrant for institutional investors and $6.50 for company insiders. Warrants will be exercisable after six months at $6.40 per share with a five-year expiration. The offering is expected to close around September 16, 2024. Proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering, which is made pursuant to an effective shelf registration statement.
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has announced its participation in the Baird 2024 Global Healthcare Conference in New York, NY. The company's management will present on Tuesday, September 10, 2024, from 8:30-9:00 AM Eastern Time in Session III, Empire Ballroom B, Mezzanine Level.
INmune Bio focuses on developing treatments that harness a patient's innate immune system to fight disease. This conference presentation provides an opportunity for the company to showcase its progress and engage with investors in the healthcare sector. The Baird Global Healthcare Conference is a significant event that brings together industry leaders and investors to discuss advancements in healthcare.
INmune Bio Inc. (NASDAQ: INMB) announced Q2 2024 results and provided a business update. Key highlights include:
1. The Phase 2 trial for XPro™ in Early Alzheimer's Disease is on track to complete enrollment by Q3 end.
2. A new Phase 1b analysis shows XPro's™ significant effects on synaptic proteins.
3. INKmune™ platform progress includes a new formulation and completion of the first cohort in the Phase I/II trial for metastatic castration-resistant prostate cancer.
4. The company raised $14.5 million in equity capital.
5. Q2 2024 financial results: Net loss of $9.7 million, R&D expenses of $7.1 million, and cash position of $31.1 million as of June 30, 2024.
INmune Bio (NASDAQ: INMB) presented new Phase 1 study data at the Alzheimer's Association International Conference, demonstrating XPro's™ dose-dependent effect on synaptic proteins in Alzheimer's patients. The 12-week treatment resulted in significant changes to proteins essential for neuron communication. This aligns with preclinical models and supports the restoration of normal immune function.
The company's VP of Neuroscience, CJ Barnum, emphasized the importance of these findings, as synaptic loss is an early and devastating consequence of Alzheimer's. CEO RJ Tesi highlighted that this cellular-level evidence supports recent EEG data showing improved synaptic function. INmune Bio is currently conducting a Phase 2 trial for mild to moderate Alzheimer's, with top-line results expected in early 2025.
FAQ
What is the current stock price of Inmune Bio (INMB)?
What is the market cap of Inmune Bio (INMB)?
What is the core focus of INmune Bio Inc?
How does the DN-TNF platform work?
What is the mechanism behind INKmune™?
What diseases are INmune Bio’s products targeting?
How does INmune Bio integrate precision medicine?
What distinguishes INmune Bio from other biotech companies?
Are INmune Bio’s therapies tumor agnostic?
What is the regulatory status of their product candidates?
